Immunoglobulin replacement treatment by rapid subcutaneous infusion.
about
TAT-mediated intracellular delivery of purine nucleoside phosphorylase corrects its deficiency in miceHealth-related quality of life in patients with primary immunodeficiency diseaseExperience with Subgam, a Subcutaneously Administered Human Normal Immunoglobulin (ClinicalTrials.gov--NCT02247141)Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic reviewIntravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies.Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease.II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies.Early B cell defects.Subcutaneous immunoglobulin-g replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: reasons and regimens.Efficacy and safety of hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiencyHome-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency.Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases.Immunoglobulin replacement therapy in children.Indications and safety of intravenous and subcutaneous immunoglobulin therapy.Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.Modern management of primary B-cell immunodeficiencies.Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again.Subcutaneous immunoglobulins: product characteristics and their role in primary immunodeficiency disease.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review.Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies.A cohort of French pediatric patients with primary immunodeficiencies: are patient preferences regarding replacement immunotherapy fulfilled in real-life conditions?A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients with Primary Immunodeficiency Diseases: A Systematic Review and Meta-Analysis.Clinical experiences in primary and secondary immunodeficiencies and immune-mediated conditions using Gammanorm(®).Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina.Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies.Primary immunodeficiency diseases in lung disease: warning signs, diagnosis and management
P2860
Q24302335-1993EB1A-6FAF-4AB8-825C-8EB3531FCBACQ26784167-D7EC0FFE-BF72-4B2B-A178-D5C396AF7B54Q28546873-C5E543C0-76B1-4036-AC5B-1BDCE9767826Q28755847-F4E07AF1-6C29-43F9-987A-201CA878169EQ33417506-A1598272-7A94-45C2-9659-7EBE82150480Q33635013-821C0607-0D10-47BB-97A3-2D196BB28C12Q33692418-F23AD276-9EA6-4DEE-BEBE-0A44DE13AEA2Q33848541-B35F7ABD-C340-4026-AAD3-856AF8211188Q33878939-98BD3A44-3E53-4295-ACA3-EA30BEB5360CQ35566525-2D5C4B5B-6995-4786-BA72-D0E274C42B5DQ35959163-00E414C5-FE39-4BAF-9CE9-7659D111F312Q36196688-2126F8DF-8AD7-45C9-A13D-1FE4CFA4FB09Q36979273-65743566-83C1-410F-9B27-7F5C532D744FQ37877259-21120D9E-A397-4F1F-98F6-2D5B71324EBDQ37890936-5DE7EB7E-1F47-4606-AC45-26BA0D42D54FQ37962045-D34FA03A-17EE-4AF7-B97D-173AB194CA64Q38021422-122C037C-9E3D-49D2-BD09-C8B07201810BQ38029244-C21634AA-6905-48CB-9A25-29036A0295F3Q38065205-746F11B8-D93F-45F8-8449-31E2F39C6B5BQ38072598-F3506309-B715-4607-B194-DA3F49B8D0BEQ38075120-1B85981F-E5EB-4C77-B417-466CBE8525C2Q38122120-0943D392-4C9A-43F6-9448-716FA899AC3BQ38217591-F95D0D10-F9E3-402D-B67A-00833A835F91Q38661420-0AC69CE6-AEF5-4DBB-8FDF-33B4ED4C6D94Q38744512-982EAC53-D804-4CA5-965F-865D9FCFDBEAQ39217483-6C4329CB-9934-4D00-8169-072467E03441Q42608614-6ED0A999-B7FD-4150-ABF1-70D26EDF9E79Q42694622-51FECE38-59CE-4C6A-9028-50A2E05F006AQ59127411-39A77A63-EAAD-4D4D-A0D1-3D21C09FDA4C
P2860
Immunoglobulin replacement treatment by rapid subcutaneous infusion.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Immunoglobulin replacement treatment by rapid subcutaneous infusion.
@ast
Immunoglobulin replacement treatment by rapid subcutaneous infusion.
@en
type
label
Immunoglobulin replacement treatment by rapid subcutaneous infusion.
@ast
Immunoglobulin replacement treatment by rapid subcutaneous infusion.
@en
prefLabel
Immunoglobulin replacement treatment by rapid subcutaneous infusion.
@ast
Immunoglobulin replacement treatment by rapid subcutaneous infusion.
@en
P2093
P2860
P356
P1476
Immunoglobulin replacement treatment by rapid subcutaneous infusion.
@en
P2093
P2860
P356
10.1136/ADC.79.1.48
P407
P577
1998-07-01T00:00:00Z